This review provides an update on the PSMA-based nanomedicine applications in PCa.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Nanomedicine is a branch of nanotechnology that includes the development of nanostructures and nanoanalytical systems for various medical applications.
📊
Key Findings & Data:New therapeutic strategies in cancer research using nanoparticles are being developed in order to improve the specificity and efficacy of drug delivery, thus reaching maximal effectiveness with minimal side effects.
💡
Conclusion & Impact:This review provides an update on the PSMA-based nanomedicine applications in PCa.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Nanomedicine is a branch of nanotechnology that includes the development of nanostructures and nanoanalytical systems for various medical applications. The rapid development of nanomedicine offers new possibilities in cancer diagnosis and treatment. New therapeutic strategies in cancer research using nanoparticles are being developed in order to improve the specificity and efficacy of drug delivery, thus reaching maximal effectiveness with minimal side effects. Due to its selective overexpression in prostate cancer (PCa), prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. This review provides an update on the PSMA-based nanomedicine applications in PCa.
🔖
Cite This Article
BOLAT, D., HAYDAROĞLU, A. (2019). Prostate-specific Membrane Antigen-Based Nanomedicine Applications in the Diagnosis and Treatment of Prostate Cancer. Üroonkoloji Bülteni, Cilt: 18 - Sayı: 1, 34–39. https://ajindex.com/articles/334381
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 1946;132:838-847.
Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatmentof differentiated thyroid carcinoma. J Nucl Med 2005;46(Suppl 1):28-37.
Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics 2012;2:437-447.
Kulkarni H, Baum RP. Molecular Imaging Using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. J Postgrad Med Edu Res 2013;47:47-53.
Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin Receptor-based Imaging and Therapy of Gastroenteropancreatic Neuroendocrine Tumors. Endocr Relat Cancer 2010;17:53-73.
Strosberg J, Wolin E, Chasen B, et al. 6LBA 177-Lu-Dotatate Significantly Improves Progression-free Survival in Patients with Midgut Neuroendocrine Tumours: Results of the Phase III NETTER-1 Trial. Eur J Cancer 2015;51(Suppl 3):710. Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015;5:1388-1401. Denmeade S. Prostate-Specific Membrane Antigen. In: Schwab M, ed. Encyclopedia of Cancer. Springer, Berlin, Heidelberg, 2011.p. 2452-2455.
Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA Theranostics: Current Status and Future Directions. Mol Imaging 2018;17:1536012118776068. Liu T, Wu LY, Kazak M, Berkman CE. Cell-Surface Labeling and Internalization by a Fluorescent Inhibitor of Prostate-specific Membrane Antigen. Prostate 2008;68:955-964.
Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.
Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneity of prostate-specific membrane antigen [PSMA] expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009;15:167-172.
Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression inprostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-6362.